dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Aluja Gonzalez, David |
dc.contributor.author | Delgado Tomás, Sara |
dc.contributor.author | Barrabés Riu, José Antonio |
dc.contributor.author | Inserte Igual, Javier |
dc.contributor.author | Ruiz Meana, Marisol |
dc.date.accessioned | 2022-09-07T11:18:10Z |
dc.date.available | 2022-09-07T11:18:10Z |
dc.date.issued | 2022-04 |
dc.identifier.citation | Aluja D, Delgado-Tomás S, Ruiz-Meana M, Barrabés JA, Inserte J. Calpains as Potential Therapeutic Targets for Myocardial Hypertrophy. Int J Mol Sci. 2022 Apr;23(8):4103. |
dc.identifier.issn | 1422-0067 |
dc.identifier.uri | https://hdl.handle.net/11351/8042 |
dc.description | Calpain; Calpastatin; Myocardial hypertrophy |
dc.description.abstract | Despite advances in its treatment, heart failure remains a major cause of morbidity and mortality, evidencing an urgent need for novel mechanism-based targets and strategies. Myocardial hypertrophy, caused by a wide variety of chronic stress stimuli, represents an independent risk factor for the development of heart failure, and its prevention constitutes a clinical objective. Recent studies performed in preclinical animal models support the contribution of the Ca2+-dependent cysteine proteases calpains in regulating the hypertrophic process and highlight the feasibility of their long-term inhibition as a pharmacological strategy. In this review, we discuss the existing evidence implicating calpains in the development of cardiac hypertrophy, as well as the latest advances in unraveling the underlying mechanisms. Finally, we provide an updated overview of calpain inhibitors that have been explored in preclinical models of cardiac hypertrophy and the progress made in developing new compounds that may serve for testing the efficacy of calpain inhibition in the treatment of pathological cardiac hypertrophy. |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | International Journal of Molecular Sciences;23(8) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Insuficiència renal aguda - Tractament |
dc.subject | Enzims - Ús terapèutic |
dc.subject.mesh | Heart Failure |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Calpain |
dc.title | Calpains as Potential Therapeutic Targets for Myocardial Hypertrophy |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/ijms23084103 |
dc.subject.decs | insuficiencia cardíaca |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | calpaína |
dc.relation.publishversion | https://doi.org/10.3390/ijms23084103 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Aluja D, Delgado-Tomás S] Grup de Recerca en Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Ruiz-Meana M, Barrabés JA, Inserte J] Grup de Recerca en Malalties Cardiovasculars, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación en Red de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain |
dc.identifier.pmid | 35456920 |
dc.identifier.wos | 000785143600001 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2017-2020/PI20%2F01681 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/CB16%2F11&2F00479 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |